Comparison of the therapeutic effect of melatonin, metformin and vitamin E in patients with non-alcoholic fatty liver disease under a diet program
Abstract
Introduction and objectives: Understanding the best treatment for non-alcoholic fatty liver (NAFLD) as its prevalence growing is necessary. In this study we evaluated and compared the therapeutic effects of three drugs metformin, vitamin E and melatonin in patients with NAFLD.
Materials and methods: This double blinded randomized clinical trial conducted on 3 groups contain 30 patients with NAFLD. For all patients we administrated same diet regimen and changing the life style by increasing the activity time of the day. Drugs administrated randomly and patients followed for 3 months. Metformin 500 mg per day, Vitamin E 400 IU per day and melatonin 3mg per day was administered. At the beginning and the end of the study, the weight of patients,BMI, liver aminotransferases, lipid factors and fasting blood glucose were evaluated. Data were analyzed by SPSS software version 20.
Results: Metformin, vitamin E and melatonin all of them were able to significantly reduce the level of aminotransferases (P <0.05). In compare of the groups, ALT, AST, cholesterol and LDL levels were significantly different between the two groups of metformin and melatonin (P <0.05). It was also observed that weight lost can independently improve disease condition.
Conclusion: Melatonin can improve the hepatic injury factors and lipid metabolism and also fasting the repairing process. Metformin also do so but especially more powerful in improving the lipid factors. Vitamin E can reduce the hepatic injury…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 30 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.